Esya is a precision diagnostics company revolutionising brain health screening by developing accessible, blood-based, AI-driven solutions. Our CNS and inflammation biomarker panel detects early neurodegenerative changes through a simple blood test, enabling brain health checks to be as routine as other preventive screenings. Leveraging AI, we transform biomarker data into actionable insights for personalised care and proactive intervention. Esya's platform not only supports clinicians but also collaborates with pharmaceutical companies to advance drug discovery by uncovering novel biomarkers and disease pathways, creating new drug targets. Our scalable model integrates with healthcare providers worldwide, offering subscription-based diagnostics and predictive analytics that empower both patients and providers. Partnering with research institutions and healthcare systems, Esya aims to set a new standard in brain health, extending our impact to patients, public health agencies, and global drug development.
What is the problem?
Brain health remains critically underprioritised in routine healthcare, resulting in missed opportunities for early intervention in neurodegenerative diseases like dementia, which often go undetected until advanced stages. Over 50 million people worldwide currently live with dementia, a number projected to reach 152 million by 2050 without advancements in early detection. Existing diagnostic methods are invasive, costly, and inaccessible to most, leaving countless patients without timely care. The lack of regular brain health screening also impedes critical research into disease biomarkers, slowing drug discovery and preventing effective monitoring of new amyloid therapies, which could benefit over 6 million Alzheimer's patients in the U.S. alone. This diagnostic gap underscores the urgent need for affordable, routine brain health monitoring that enables early intervention, supports proactive care, and facilitates effective treatment tracking to advance neurodegenerative drug development worldwide.
What is their solution?
Esya's solution is an AI-powered, blood-based CNS and inflammation biomarker panel designed to make brain health screening as routine and accessible as a cholesterol test. Through a simple blood test, our panel captures biomarker data that enables early detection of neurodegenerative diseases and personalised care at scale. Our AI platform processes this data to monitor disease progression in real time, giving clinicians actionable insights while supporting drug discovery by identifying new biomarkers and pathways for targeted therapies. Esya's subscription model for healthcare providers and partnerships with pharmaceutical companies ensure sustainable revenue, while direct-to-patient services empower individuals to proactively manage brain health. Through continuous data refinement and predictive analytics, Esya redefines brain health care, setting a new standard for proactive, comprehensive management that benefits patients, providers, and researchers worldwide
